Search research articles
Contact Us
Filters
Showing results (61-70 of 172) with videos related to
Page
of 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 14, 2021
Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
Matthew D Hellmann, Nicoletta Bivi, Boris Calderon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 14, 2018
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Neal Ready, Anna F Farago, Filippo de Braud, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 12, 2016
Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas
M C Pietanza, Matthew D Hellmann, John J Fiore, et al.
Cancer Cell
|
June 13, 2018
Non-conventional Inhibitory CD4<sup>+</sup>Foxp3<sup>-</sup>PD-1<sup>hi</sup> T Cells as a Biomarker of Immune Checkpoint Blockade Activity
Roberta Zappasodi, Sadna Budhu, Matthew D Hellmann, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 4, 2020
Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab
Michael Offin, Narek Shaverdian, Andreas Rimner, et al.
Cancer Cell
|
October 10, 2018
Non-conventional Inhibitory CD4<sup>+</sup>Foxp3<sup>-</sup>PD-1<sup>hi</sup> T Cells as a Biomarker of Immune Checkpoint Blockade Activity
Roberta Zappasodi, Sadna Budhu, Matthew D Hellmann, et al.
Journal for Immunotherapy of Cancer
|
June 1, 2022
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
Miguel Lopez de Rodas, Venkata Nagineni, Arvind Ravi, et al.
Cancer Discovery
|
August 21, 2020
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
Qu Zhang, Jia Luo, Song Wu, et al.
Cancer Cell
|
February 13, 2019
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Matthew D Hellmann, Margaret K Callahan, Mark M Awad, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 20, 2021
CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
Michael D Farwell, Raymond F Gamache, Hasan Babazada, et al.
Page
of 18
Search research articles
Search
Showing results (61-70 of 172) with videos related to
Sort By:
Page
of 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 14, 2021
Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
Matthew D Hellmann, Nicoletta Bivi, Boris Calderon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 14, 2018
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Neal Ready, Anna F Farago, Filippo de Braud, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 12, 2016
Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas
M C Pietanza, Matthew D Hellmann, John J Fiore, et al.
Cancer Cell
|
June 13, 2018
Non-conventional Inhibitory CD4<sup>+</sup>Foxp3<sup>-</sup>PD-1<sup>hi</sup> T Cells as a Biomarker of Immune Checkpoint Blockade Activity
Roberta Zappasodi, Sadna Budhu, Matthew D Hellmann, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 4, 2020
Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab
Michael Offin, Narek Shaverdian, Andreas Rimner, et al.
Cancer Cell
|
October 10, 2018
Non-conventional Inhibitory CD4<sup>+</sup>Foxp3<sup>-</sup>PD-1<sup>hi</sup> T Cells as a Biomarker of Immune Checkpoint Blockade Activity
Roberta Zappasodi, Sadna Budhu, Matthew D Hellmann, et al.
Journal for Immunotherapy of Cancer
|
June 1, 2022
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
Miguel Lopez de Rodas, Venkata Nagineni, Arvind Ravi, et al.
Cancer Discovery
|
August 21, 2020
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
Qu Zhang, Jia Luo, Song Wu, et al.
Cancer Cell
|
February 13, 2019
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Matthew D Hellmann, Margaret K Callahan, Mark M Awad, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 20, 2021
CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
Michael D Farwell, Raymond F Gamache, Hasan Babazada, et al.
Page
of 18